BioSpace News Archive

Innovent Biologics, Inc. presents latest data of two ophthalmic bispecific antibodies at the American Academy of Ophthalmology 2023 Annual Meeting, including a Phase 2 clinical study of anti-VEGF and anti-complement bispecific fusion protein for neovascular age-related macular degeneration and a Phase 1 clinical study of anti-VEGF-A/Ang-2 bispecific antibody for diabetic macular edema.

MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, announced positive top-line results from its global Phase 2 ARGO trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with active psoriatic arthritis.

Elpiscience Biopharmaceuticals, Inc. presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting, including KG2A/NKG2C dual-targeting antibody ES015-2, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014.

Olink Holding AB announced that Novogene Asia Pacific Middle East and Africa has adopted the Olink Explore HT platform to deliver advanced next-generation proteomics technology to the scientific community in the region.

SK bioscience announced that H.E Dr. Jean Kaseya, Director General of Africa CDC visited SK bioscience headquarters on November 3 to discuss collaboration with the Partnerships for African Vaccine Manufacturing.

Nido Biosciences announced positive results from its Phase 1 study of NIDO-361 in healthy male subjects and interim results from its observational study at the 2023 International Kennedy’s Disease Patient Conference in London, November 4 – 5.

Celldex Therapeutics, Inc. announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis.

GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of “GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency, to the Korean Ministry of Food and Drug Safety.

Gannex Pharma Co., Ltd., a wholly-owned company of Ascletis Pharma Inc. announces that the safety, pharmacokinetics, and pharmacodynamics data of ASC42, a novel farnesoid X receptor agonist, in healthy subjects have been published on the journal Drugs in R&D.

Tokyo, Japan and Cambridge, UK,06 November 2023 – Sosei Group Corporation has been notified by Pfizer that it has entered a new oral small molecule GLP-1 receptor agonist into a Phase 1 clinical trial.